Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TriSalus Life Sciences (TLSIW) Equity Ratio (2022 - 2025)

Historic Equity Ratio for TriSalus Life Sciences (TLSIW) over the last 4 years, with Q3 2025 value amounting to 0.73.

  • TriSalus Life Sciences' Equity Ratio rose 144.44% to 0.73 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.73, marking a year-over-year increase of 144.44%. This contributed to the annual value of 1.08 for FY2024, which is 182.41% up from last year.
  • Latest data reveals that TriSalus Life Sciences reported Equity Ratio of 0.73 as of Q3 2025, which was up 144.44% from 0.47 recorded in Q2 2025.
  • Over the past 5 years, TriSalus Life Sciences' Equity Ratio peaked at 0.25 during Q3 2023, and registered a low of 16.21 during Q2 2023.
  • In the last 4 years, TriSalus Life Sciences' Equity Ratio had a median value of 0.74 in 2024 and averaged 2.74.
  • Data for TriSalus Life Sciences' Equity Ratio shows a peak YoY increase of 64522.8% (in 2023) and a maximum YoY decrease of 3508606.31% (in 2023) over the last 5 years.
  • Quarter analysis of 4 years shows TriSalus Life Sciences' Equity Ratio stood at 8.02 in 2022, then skyrocketed by 86.28% to 1.1 in 2023, then increased by 1.82% to 1.08 in 2024, then skyrocketed by 32.15% to 0.73 in 2025.
  • Its Equity Ratio stands at 0.73 for Q3 2025, versus 0.47 for Q2 2025 and 1.2 for Q1 2025.